Diabetic Nephropathy R&D Services
Ace Therapeutics specializes in preclinical research and development for diabetic nephropathy. Leveraging customized disease models, integrated pathology research platforms, and multi-omics technologies, we provide end-to-end solutions for global pharmaceutical companies, biotech firms, and research institutions. Focusing on target discovery, innovative drug development, and diagnostic translation, we are committed to helping our clients accelerate their diabetic nephropathy research and development process and minimize the risk of drug development.
Introduction of Diabetic Nephropathy
Diabetic nephropathy (DN) is a major long-term microvascular complication of type 1 and type 2 diabetes. Although factors such as hyperglycemia, hyperlipidemia, hypertension and proteinuria have been found to contribute to the progression of renal impairment in DN, the exact pathogenesis remains unknown. Furthermore, there is a paucity of conventional therapeutic options and an absence of accurate early diagnostic tools. Therefore, it is important to elucidate the pathogenesis of diabetic nephropathy and develop new therapeutic approaches.
Fig. 1 Mechanisms involved in the pathogenesis of diabetic kidney disease. (Pelle, M. C.; et al., 2022)
Diabetic Nephropathy R&D Services at Ace Therapeutics
Ace Therapeutics provides one-stop R&D services to help clients make progress in diabetic nephropathy research with its deep technology deposits and rich industry experience.
We help our clients explore the pathogenesis and pathology of diabetic nephropathy at different levels through a variety of advanced technologies.
- Through high-resolution microscopic imaging techniques and molecular biology assays, we elucidate the mechanisms of disease initiation and progression at cellular and molecular levels.
- Custom-developed diabetic nephropathy (DN) animal models replicate human disease phenotypes, offering a robust platform to investigate disease pathogenesis and pathological progression.
- Conduct histopathology and molecular pathology analyses to clarify the biomarkers and key pathways related to diabetic nephropathy, and provide data support for target validation and therapy development.
We provide customized diabetic nephropathy models according to our clients' needs. Our diverse model building methods and rigorous model validation ensure that we can develop diabetic nephropathy models with good structural, surface and predictive validity.
- Diabetic nephropathy modeling: High-fat diet + streptozotocin (STZ)-induced type 2 diabetic nephropathy model, db/db mouse spontaneous type 2 diabetic nephropathy model.
- Diabetic nephropathy model validation: Blood glucose monitoring, body weight tracking, serum creatinine measurement, urinary protein quantification, histopathological analysis.
Ace Therapeutics provides innovative diabetic nephropathy drug discovery and development services based on a deep understanding of the pathogenesis of diabetic nephropathy.
- One-stop drug discovery process: We offer a seamless workflow covering target identification and validation, candidate compound screening, efficacy assessment, and preclinical safety evaluation.
- Innovative drug development solutions: Covering the full process of development of small molecules, biologics and natural products. Whether it is a validated target or a novel target, we can provide customized drug development services.
- Comprehensive preclinical evaluation system
| In vitro efficacy |
Podocyte apoptosis assay |
| In vivo efficacy |
Multidimensional validation of renal function (serum creatinine, urea nitrogen), pathological scores (glomerulosclerosis index, interstitial fibrosis area) and biomarkers (KIM-1, NGAL). |
We provide clients with integrated solutions for biomarker development, covering discovery, validation, and clinical translation, to empower breakthroughs in the diagnosis and treatment of diabetic nephropathy.
- Leveraging proteomics, metabolomics, and epigenetic analysis of urine/serum samples, we enable high-throughput screening of potential biomarkers.
- Conducting rigorous validation experiments to ensure biomarker specificity and sensitivity.
We combine the results of diabetic nephropathy biomarker research with innovative diagnostic technology and product development services, covering a wide range of aspects such as in vitro diagnostic reagent development and diagnostic device development.
- We use immunoassay and molecular diagnostic technologies to develop highly sensitive and specific diagnostic products.
- We provide our clients with technical support for the registration and declaration of diagnostic products, and assist them in the rapid introduction of diagnostic products to the market.
Advantages of Our Diabetic Nephropathy R&D Services
- Professional team: Gathering experts in the fields of diabetology and pharmacology with years of experience in diabetic nephropathy research, we are able to accurately grasp the direction of research.
- Advanced technology: Advanced experimental equipment and cutting-edge technology platform to ensure the accuracy and reliability of research data.
- Customized solutions: Tailor-made R&D solutions according to different needs of clients to meet diversified research requirements.
Ace Therapeutics offers flexible and diverse collaboration models. Whether it is a long-term strategic cooperation or a single project commission, we will meet your needs with professional attitude and efficient service. If you are interested in R&D service for diabetic nephropathy, please feel free to contact us, and we will provide you with a detailed proposal and quotation.
References
- Pelle, M. C.; et al. Up-date on diabetic nephropathy. Life. 2022, 12(8): 1202.
- Rao, V.; et al. Diabetic nephropathy: an update on pathogenesis and drug development.
- Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019, 13(1): 754-762.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
